BIOMARKER:

EGFR mutation + BRAF V600E

Entrez ID:

Related biomarkers:

‹

›

EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials	cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials
EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials	cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials
EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib Resistant: C3 – Early Trials	cetuximab + encorafenib Resistant: C3 – Early Trials
EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Non Small Cell Lung Cancer NSCLC	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + osimertinib + dabrafenib Sensitive: C4 – Case Studies	trametinib + osimertinib + dabrafenib Sensitive: C4 – Case Studies
EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Lung Adenocarcinoma LUAD	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + erlotinib Sensitive: D – Preclinical	trametinib + erlotinib Sensitive: D – Preclinical
EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Lung Adenocarcinoma LUAD	EGFR mutation + BRAF V600E EGFR mutation + BRAF V600E	Lung Adenocarcinoma LUAD	erlotinib Resistant: D – Preclinical	erlotinib Resistant: D – Preclinical